Related Experiment Video

Updated: May 22, 2026

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Reducing clinical inertia in hypertension treatment: a pragmatic randomized controlled trial

Amy G Huebschmann1, Trina Mizrahi, Alyssa Soenksen

  • 1Division of General Internal Medicine, University of Colorado School of Medicine, Academic Office 1, 12631 East 17th Avenue, Mailstop B180, Aurora, CO 80045, USA. amy.huebschmann@ucdenver.edu

Journal of Clinical Hypertension (Greenwich, Conn.)
|April 27, 2012
PubMed

Insights

This study found that an intervention effectively reduced clinical inertia, which is the failure to adjust treatment when blood pressure (BP) goals are not met. However, the intervention did not significantly improve overall BP control in primary care patients.

Area of Science:

  • Internal Medicine
  • Cardiovascular Disease Prevention
  • Primary Care Practice Management

Background:

  • Clinical inertia significantly hinders effective blood pressure (BP) management.
  • Addressing physician, patient, and system factors is crucial for improving BP control.

Purpose of the Study:

  • To evaluate an intervention designed to overcome clinical inertia and enhance BP control in primary care.
  • To assess the impact of an outreach coordinator on patient and provider BP management.

Main Methods:

  • A randomized controlled trial involving 591 adult primary care patients with elevated BP.
  • Intervention group received enhanced support, including awareness campaigns, BP-focused visits, and decision support.
  • Control group received usual care.

Main Results:

  • The intervention significantly reduced clinical inertia by 29% compared to 11% in the usual care group (P=.001).
  • No significant difference in systolic or diastolic BP reduction was observed between the intervention and usual care groups.
  • Mean systolic BP change: -10.1 mm Hg (intervention) vs -9.1 mm Hg (usual care).
  • Mean diastolic BP change: -4.1 mm Hg (intervention) vs -4.5 mm Hg (usual care).

Conclusions:

  • While the intervention successfully reduced clinical inertia, it did not lead to improved blood pressure control.
  • Future interventions should incorporate medication titration protocols, adherence support, and sustained patient follow-up.
  • Optimizing primary care strategies is essential for achieving target blood pressure levels.

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...